Amgen Inc. (NASDAQ:AMGN) Shares Bought by Neville Rodie & Shaw Inc.

Neville Rodie & Shaw Inc. raised its position in Amgen Inc. (NASDAQ:AMGN) by 4.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,790 shares of the medical research company’s stock after acquiring an additional 160 shares during the period. Neville Rodie & Shaw Inc.’s holdings in Amgen were worth $1,181,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of AMGN. Tallon Kerry Patrick acquired a new stake in Amgen in the fourth quarter valued at approximately $270,000. Brighton Jones LLC boosted its stake in Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares in the last quarter. Blue Trust Inc. boosted its stake in Amgen by 38.4% in the fourth quarter. Blue Trust Inc. now owns 5,095 shares of the medical research company’s stock valued at $1,328,000 after acquiring an additional 1,413 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new stake in Amgen in the fourth quarter valued at approximately $694,000. Finally, Perigon Wealth Management LLC boosted its stake in Amgen by 25.1% in the fourth quarter. Perigon Wealth Management LLC now owns 16,145 shares of the medical research company’s stock valued at $4,350,000 after acquiring an additional 3,236 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Down 0.4%

Shares of Amgen stock opened at $278.40 on Thursday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The firm has a fifty day moving average price of $284.48 and a 200 day moving average price of $285.76. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The stock has a market cap of $149.70 billion, a PE ratio of 36.87, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion during the quarter, compared to analysts’ expectations of $8.05 billion. During the same quarter last year, the company posted $3.96 earnings per share. The firm’s revenue was up 9.4% compared to the same quarter last year. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.42%. Amgen’s payout ratio is 86.86%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on AMGN shares. Bank of America lifted their price objective on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research note on Wednesday, March 5th. Citigroup reiterated a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. UBS Group reiterated a “neutral” rating and set a $315.00 price objective (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Johnson Rice set a $294.00 price objective on shares of Amgen in a research note on Wednesday, March 5th. Finally, Piper Sandler lowered their price objective on shares of Amgen from $329.00 to $328.00 and set an “overweight” rating for the company in a research note on Friday, May 16th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $309.22.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.